Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Immunol. 2008 Apr;20(2):123-9. Epub 2007 Dec 21.

Recent advancements towards the derivation of immune-compatible patient-specific human embryonic stem cell lines.

Author information

1
Institute for Stem Cell Biology and Regenerative Medicine, Beckman Center B261, Stanford, CA 94305-5323, USA. dmicha@stanford.edu

Abstract

The derivation of human embryonic stem cell lines from blastocyst stage embryos, first achieved almost a decade ago, demonstrated the potential to prepare virtually unlimited numbers of therapeutically beneficial cells in vitro. Assuming that large-scale production of differentiated cells is attainable, it is imperative to develop strategies to prevent immune responses towards the grafted cells following transplantation. In this review, I will discuss recent advances in the production of pluripotent cell lines using three emerging techniques: somatic cell nuclear transfer into enucleated oocytes and zygotes, parthenogenetic activation of unfertilized oocytes and induction of pluripotency in somatic cells. Importantly, if these techniques can be harnessed for generating patient-specific pluripotent cell lines, then immunological processes are expected to be low or completely absent.

PMID:
18160306
DOI:
10.1016/j.smim.2007.11.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center